Featured Articles
High-end MRI scanner adapts automatically to individual anatomical and physiological characteristics
/in Featured ArticlesMagnetom Vida, the new high-end 3-Tesla MRI scanner with BioMatrix
technology from Siemens Healthineers, was launched to the public at University Hospital Tübingen, where the first system is installed. It has been undergoing clinical tests in the hospital’s Department for Diagnostic and Interventional Radiology since December 2016.
Magnetom Vida is the first scanner equipped with BioMatrix, a brand-new, innovative scanner technology that addresses inherent anatomical and physiological differences among individual patients, as well as variability among users. Magnetom Vida and BioMatrix allow users to meet the growing demand for MR imaging, perform the full range of routine as well as complex examinations, and deliver robust results for every patient. Furthermore, the scanner also makes MRI more cost-effective by reducing rescans and increasing productivity. High-precision imaging means that radiologists can deliver essential and robust information to choose the right treatment for each patient every time. Siemens Healthineers, in collaboration with its customers, is playing an important role in taking healthcare forward in the development of precision medicine.
Siemens Healthineers has been developing this disruptive and innovative BioMatrix technology for over five years. Its introduction represents a further advance in MRI imaging as well as the next level of automation and patient centricity.
High image quality and efficient workflows – regardless of user or patient
Due to high levels of exam variability, MRI is often considered to be one of the most complex medical imaging modalities. Physiological and anatomical differences between patients as well as different experiences levels in users contribute to this unwanted variability. This frequently is a source of errors, rescans, and inefficient workflows in MR imaging, making it all the more important that MRI scanners deliver reliable and reproducible image data irrespective of the patient being examined or the person operating the system. This issue is precisely addressed with the new BioMatrix technology.
BioMatrix sensors in the table automatically track a patient’s respiratory pattern, giving users insights into a patient’s individual ability to hold his or her breath during the scan. This allows the user to select the optimal exam strategy, while also saving time during the examination. BioMatrix tuners can help avoid rescans, which represent a major burden on productivity as well as a driver of additional costs in radiology. In cervical spine examinations, for example, this feature uses intelligent coil technology to automatically set the optimal scan parameters based on the individual patient anatomy, all without any additional user interaction. BioMatrix tuners also improve the quality and reproducibility of whole-body diffusion. Precise control of scan parameters in real-time to match the individual patient anatomy makes it possible to avoid distortions, which can render diffusion imaging non-diagnostic, especially in 3 Tesla MRI. Innovative interfaces also help ensure a consistently high examination quality, accelerating workflows, and improving quality of care. BioMatrix Interfaces accelerate the scanning process by up to 30 percent. Automated patient positioning based on intelligent body models automatically moves the patient table to the correct scan position. An intuitive touchscreen user interface integrated onto the scanner allows for one-touch positioning. A new, easy-to-move motorized patient table further simplifies examinations, especially for adipose, immobile, and trauma patients.
Magnetom Vida is the first system to be equipped with the new BioMatrix technology, designed to tackle the challenges of variability and thereby, reduce unwanted variability in MRI examinations. It will help users achieve fewer rescans, predictable scheduling, and consistent, high-quality personalized examination results.
The ability to provide consistent and reproducible quality regardless of the individual patient and user will help reduce rescans, which can be a great financial burden for healthcare institutions. As publications have shown, rescans can account for up to €100,000 per year and system in additional costs.
Professor Konstantin Nikolaou, Medical Director of the Department of Diagnostic and Interventional Radiology at University Hospital Tübingen considers Magnetom Vida to be part of the general trend toward precision medicine: “To provide our patients with individual therapies, we need every piece of information available. When it comes to imaging, this means that we need robust, standardized, and reproducible image data that are always of the same quality regardless of the patient or user. Only then we can compare results and link them with additional information, such as data from laboratory medicine or genetics,” says Nikolaou, referring to the clinical validation of the new MRI scanner in his department. “Magnetom Vida gives us this data quality and comprehensive image information so that we can choose the right kind of personalized therapy and evaluate it – to see, for instance, how a patient responds to chemotherapy before tumour removal. This MRI scanner along with BioMatrix technology is the perfect fit for our current medical approaches, and is helping us on our way to quantitative radiology,” says Nikolaou.
Faster scans with very high patient comfort
Magnetom Vida has another major advantage: “We can examine sick patients faster with Magnetom Vida,” says Professor Mike Notohamiprodjo who, as head of MRI at University Hospital Tübingen, works intensively with the new scanner. “The scanner offers the highest degree of patient comfort with the performance of a research system, which speeds up our workflows,” he says. As examinations in Tübingen show, the new scanner decreases measurement times for musculoskeletal and prostate imaging compared to previous MRI systems. What is more, it does so with significantly improved image quality: “The signal-to-noise ratio in the clinical images is up to 30 percent higher than with systems from the previous generation,” says Notohamiprodjo.
While this is partly due to BioMatrix technology, it is also a result of the diverse insights that developers at Siemens Healthineers gathered from intense fundamental research and close customer collaborations. Key learnings from the development of a 7-Tesla research MRI system translated into a new 3-Tesla magnet design. Magnetom Vida’s all-new system architecture offers extremely high performance and unmet long-term stability – without requiring any more space than previous clinical systems. The new scanner’s 60/200 XT gradient system provides over 2.7 megawatts of power, making it the most powerful commercially available gradients in a 70-centimeter bore scanner. And, thanks to a very large field of view (55x55x50 cm), Magnetom Vida can also cover larger body regions in one step, such as full coverage abdominal exams.
The result is a great increase in productivity for routine examinations of the brain, spine, and joints – from correct patient positioning at the touch of a button to transferring the clinical images to the PACS archiving system. This is made possible by the GO technologies, which automate and simplify workflows from the start of the scan right through to the quality control of the image data. A new user interface allows not only for automated acquisition and processing, but also for more advanced post-processing applications to run at the scanner. With spine examinations, for instance, GO technologies reduce the time needed by about a fifth. This means that a department could carry out four additional spine examinations per day and per system. Given the decline in reimbursement rates, this is of great value to many radiological institutes.
Broader patient groups and new clinical growth areas
The system also allows customers to access additional clinical growth fields – for instance, by serving patient groups that were previously deemed unsuitable for MRI due to issues such as cardiac arrhythmias, excess weight, or health problems that prevent them from actively supporting the scan. With the introduction of Magnetom Vida, Siemens Healthineers expands its Compressed Sensing applications – which can make MRI scans up to ten times faster – to cover more body regions. It features Compressed Sensing Cardiac Cine, which allows free-breathing cardiology examinations (even when using contrast medium for comprehensive tissue characterization). Now, Compressed Sensing Grasp-Vibe, which enables dynamic, free-breathing liver examinations in one comprehensive scan by the push of button and for every patient, is also available. Until today, in contrast, dynamic liver imaging required four steps with exhausting breath-holds and complex timing. Grasp-Vibe technology also makes the post-processing of liver images significantly faster. During the studies he carried out in Tübingen, Professor Notohamiprodjo found that post-processing times fell from 20 to just four minutes.
Magnetom Vida even simplifies whole-body scans, which are currently particularly challenging, because they have to cover multiple scan sections and demand highly trained users. A new special technology, the Whole-Body Dot Engine, allows these difficult scans to be carried out in predictable time slots, as short as 25 minutes, with very high quality. This is accomplished through intelligent automation. The planning and execution of the scan requires only a few simple clicks. Providing high-quality diffusion weighted imaging is important for whole body exams; Magnetom Vida, with its BioMatrix Tuner technology, can deliver this distortion-free. Combined also with its strong 60/200 gradients and a large homogeneous field of view, Magnetom Vida makes whole-body examinations simple to perform, reproducibly, and with very high-quality. This is a major advantage, particularly when treating oncology patients, such as those with multiple myeloma, where guidelines have recently been moving toward whole-body MRI scans for therapy control.
Magnetom Vida offers not only numerous clinical advances, but also a number of improvements in energy consumption. These help to lower the total cost of ownership of the system over its entire life-cycle. Technologies such as Eco-Power provide an intelligent control of power-hungry components by switching them off when they are not needed for longer periods of time. The result is a MR scanner that consumes 30 percent less energy than the industry average for 3-Tesla scanners, as reported by the European Coordination Committee of the radiological, electromedical and healthcare IT industry (COCIR).
Women and diabetes – questions on gender-specific impact
/in Featured ArticlesAccording to the World Health Organization’s ‘Global Report on Diabetes’ 2016, diabetes is directly responsible for 1.5 million deaths around the world. This makes it the eighth leading cause of mortality. However, its impact is higher in women, for who diabetes is the fifth leading cause of death. At present, more than 200 million women are estimated to live with diabetes.
One reason for the problem of diabetes in women is the rise in the number of patients with the disease. The prevalence of diabetes, according to the WHO, has doubled since 1980. Moreover, it is no longer a disease that largely affects rich nations. Indeed, prevalence is now growing quickest in middle-income countries. More than half of the total number of women with diabetes today live in southeast Asia and the Western Pacific.
Another issue here is the the lack of healthcare. This means that the management of diabetes is inadequate, particularly for poorer people.
Debate dates to end of 1990s
The debate about gender and diabetes began to intensify at the end of the 1990s, as epidemiology improved, especially outside Western countries.
In January 2001, a report by University of Bristol researchers in ‘Diabetologia’ found geography and gender to be a major factor in Type I diabetes. The report found an excess of male patients in regions with the highest incidence of diabetes, above all in populations of European origin. These showed a roughly 3:2 ratio of males to females in the 15-40 age group. On the other side of the equation, lowest risk populations for Type I diabetes (principally non-European) typically showed a female bias.
The Bristol researchers also observed that Type II diabetes had shown an excess of females in the first half of the 20th century but had become equally prevalent among men and women in most populations, with some evidence of male preponderance in early middle age. Men seemed to also be more susceptible than women “to the consequences of indolence and obesity, possibly due to differences in insulin sensitivity and regional fat deposition.” In addition, women were more likely to transmit Type II diabetes to their offspring.
Geography and gender
Recent figures from the WHO on mortality from high glucose confirm the dual impact of gender and geography. The data shows a fork in female mortality, from near equivalence to males in the Eastern Mediterranean, Africa and the Western Pacific, to being about three fourths of male mortality in Europe, the Americas and South-East Asia.
Women may also be more prone to dying from diabetes due to physiological factors. Data show that women with diabetes are more likely than male patients to have poor blood glucose control and be overweight, along with high blood pressure and cholesterol levels. The latter impact directly on cardiac risk factors, and do so in seemingly different ways for men and women.
Male death rates fall, women’s stays unchanged
In 2007, a study in the ‘Annals of Internal Medicine’ revealed a disturbing fact – that women with diabetes fared far worse than men. The study found that in 1971-2000, death rates for diabetic men fell, while the rate for women hardly changed. Worse, while men with diabetes lived on average for 7.5 fewer years than those who did not have the disease, the difference for women was 8.2 years. This disparity is probably due to a combination of multiple factors, according to the study.
Physiological factors and standards of treatment
Most factors are physiological. However, it seems outcomes for women with diabetes may also be worse due to differences in standards of care and treatment. Some of these were highlighted in 2005 in ‘Diabetes Care’, or two years before the ‘Annals of Internal Medicine’ study mentioned above.
The ‘Diabetes Care’ article covered risk factors in coronary heart disease (CHD) and treatment for Type II diabetes. It found that women with diabetes “received less treatment for many modifiable CHD risk factors than diabetic men.” This included staple therapies such as medication for high LDL cholesterol. The authors concluded that “more aggressive treatment of CHD risk factors” in women offered “a specific target for improvement in diabetes care.”
In 2010, a study in ‘Diabetic Medicine’ found the picture to be similar for Type I diabetes. The study by another Massachusetts General Hospital team, led by M.E Clarkin, found women reported lower use than men of medications to reduce CHD risk. These included glycated hemoglobin, as well as aspirin, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and statins.
The role of cardiac health
Key physiological differences do indeed concern cardiac health.
In the general population, women tend to live longer than men, mainly because of lower rates of heart disease. However, such an advantage becomes insignificant for diabetic women. Indeed, the risk of heart disease is reported to be six times higher for women with diabetes than those without, compared to an increase of just 2-3 times in men.
This impacts directly on mortality for several reasons. One of the most significant is that women can have heart attacks without its most notable symptom in males, namely chest pain. Indeed, women are more likely to experience only nausea, shortness of breath, and back or jaw pain during a heart attack. Many women and medical practitioners in poorer parts of the world do not recognize the latter as warning signs. This lowers the chance of recovery.
One study published in the ‘European Heart Journal’ in 2007 found a stronger association between diabetes and death by heart failure for women than men. A Finnish study also found that heart attacks are more often fatal for women with diabetes than they are for men.
Indeed, perception is linked to less effective health care for women with diabetes, and this is best typified by cardiac health. As women are less likely to have heart attacks than men, a woman may not raise the same alarm bells as a man, especially when she does not experience chest pain.
Renal disease
Women with diabetes face complications from renal disease, too. Men have a higher risk for kidney disease, but this disappears with the onset of diabetes. Women with diabetes are just as likely to get kidney disease as men. Moreover, such a likelihood is not dependent on age, although women tend to be unaffected by kidney disease until menopause, when a drop in oestrogen levels makes the female endocrine system more like a male’s.
Some studies have found that lower oestrogen levels are associated with kidney disease, but the mechanisms of this association are not yet clear. One theory is that high testosterone, which kicks in as estrogen levels drop, is responsible. Should this be proven clinically, it may be possible for women with diabetes to use hormone therapy to restore the balance between estrogen and testosterone, and thereby improve their kidney health.
Mental health
Depression is about twice as common in women as men and is believed to worsen the outlook for women with diabetes. A study of women in the ‘Archives of Internal Medicine’ in 2010 suggests a two-way relationship between depression and diabetes risk, with each influencing the other. Indeed, some women-only studies have shown women with both conditions are twice as likely to die early as those who had neither. In 2006, a study in ‘Public Health’ extended the scope to men and found that diabetes and depression were not associated in men, unlike in women.
Polycystic ovary syndrome
Women with diabetes are also likely to have several conditions which are female-specific.
One of these is polycystic ovary syndrome (PCOS), a metabolic disorder caused by hormonal imbalance in the female body. PCOS causes irregular periods and can result in fertility problems. It is also associated with acne, darkening of facial skin and hair growth on the face, loss of hair on the head etc. Females with PCOS are at heightened risk of getting diabetes, and the above signs are thus potential indicators of impending diabetes.
The precise mechanism of PCOS is not known, but there is clinical evidence that women with PCOS develop high levels of resistance to insulin and this then leads to development of Type II diabetes.
What has however been confirmed is that women diagnosed with PCOS at an early age show a higher risk of diabetes and fatal heart conditions later in life.
Gestational diabetes mellitus
Women also face the risk of gestational diabetes mellitus (GDM). This is defined as blood glucose values above normal but below those of diabetes. GDM is diagnosed through screening, since several of its symptoms such as increased thirst and urination needs, dry mouth and fatigue are commonplace in pregnancy and are not necessarily a sign of a problem.
Although the true prevalence of GDM is unknown, it is estimated to affect 1-14% of pregnancies in the US, depending on the population studied and the diagnostic tests used. Recent research has focused on high-risk groups. A pan-European study of women with body mass index greater than 29 kg/m2 found prevalence of 24% in early pregnancy, with another 14% developing GDM at mid gestation (24-28 weeks) and 13% at late gestation (35-37 weeks). The study was published in the October 2017 issue of ‘Diabetologia’ and covered women at 11 centres across Europe.
GDM increases the risk of certain complications during pregnancy and delivery, both for the women in question and for their infants. One of these is pre-eclampsia, which causes high blood pressure during pregnancy. Others include the baby growing larger than usual and polyhydramnios, which is the presence of excess amniotic fluid.
Though GDM is a temporary condition, affected women have an over-sevenfold increase in the risk of developing Type II diabetes 5-10 years after delivery. Moreover, children born to mothers with GDM are also more likely to develop impaired glucose tolerance.
Early diagnosis of GDM through testing for blood sugar and modifications to lifestyle can be effective in preventing or delaying the condition and treating its consequences.
Improving diagnostic process and speeding treatment pathways
/in Featured ArticlesAdvances in in-vitro diagnostics (IVD) point-of-care (POC) technology have made it possible to bring the diagnostic power of the central laboratory to the patient, reducing waiting time and in turn improving outcomes [1]. A good starting point and significant pathological area for the use of IVD POC systems is cardiovascular disease. The World Health Organization predicts the number of deaths from cardiovascular disease to increase from 17 million to 23 million people per year by 2030 [2].
Innovations which accelerate diagnostic process have a key role to play in global efforts to reduce these numbers. For example, at Philips, we have enlisted the power of magnetic nanobeads to deliver a next generation of stable and rapid cardiac markers blood testing for suspected acute cardiac patients on the Minicare I-20 handheld immunoassay device, launched last year. With Minicare I-20, the emergency department (ED) can now run a cTnI test next to the patient, and obtain the result within 10 minutes.
The advantages of robust, accurate POC tests are particularly relevant to clinicians working in the ED and ambulance setting where having access to shortened assay turnaround time may improve outcomes. With near-patient testing, it is no longer necessary to send the blood sample to the hospital laboratory and wait up to 60 minutes for the results to come back.
Reduces crowding and patient waiting times
When patients present with symptoms of a heart attack, there is a critical need to make rapid yet precise decisions. However, only about 10% of patients can be accurately diagnosed as AMI based on an ECG [3]. Most patients presenting with suspected heart attack require blood tests, predominately the gold standard troponin biomarker. Serial testing of cTn is part of the recommended diagnostic protocol that aids in ruling in, or ruling out, Myocardial Infarction (MI). The availability of a sensitive and accurate point-of-care test for cardiac troponin could allow clinicians to reduce the standard serial testing of cTn at presentation and six hours after to a safe zero-three hour rule out protocol.
The use of point-of-care testing (POCT) in the ED and ambulance setting to reduce turnaround time for assay results has the potential to improve overall efficiency, by reducing crowding and the length of stay in acute care. Further, for the patient, it can reduce the stress of waiting for their results, and the time to diagnosis and initiation of therapy.
To make the most efficient use of hospital resources, near-patient testing protocols need to be integrated into the acute care workflow and the patient care pathway reorganized, with the full support of the clinical teams and their managers [4]. We are already seeing closer cooperation between clinical teams and the central laboratory, as they recognize the need to help reduce crowding in the ED by supporting the use of POC testing to speed up the delivery of certain blood test results.
BNP assays for rapid ruling out of acute heart failure
Critical cardiovascular disease also covers acute heart failure (AHF), the most common cause of hospitalization in patients aged over 65 years. A brain natriuretic peptide (BNP) test measures the amount of the BNP hormone in the blood. Acute heart failure is a serious condition that accounts for 5% of all emergency admissions in Europe and USA and patients presenting with AHF require immediate treatment [5]. International guidelines recommend the use of the BNP biomarker to rule-out acute heart failure (AHF) in patients presenting with acute dyspnea.
The ED clinician needs to be able to distinguish AHF as quickly as possible. Minicare BNP is the second cardiac marker assay to be introduced on the Philips Minicare I-20 handheld analyser. It provides the ED clinician with access to a fast and accurate BNP marker test to help rule out acute heart failure patients more quickly. Like the first Philips Minicare cTnI assay, Minicare BNP provides clinicians with lab comparable results, and clinically significant information within 10 minutes. It is expected to be commercially available later this year.
The Minicare I-20 platform and both cardiac marker assays are simple and easy to use by non-laboratory POC staff. Its integrated calibration and fail-safe functionalities ensure the robustness and accuracy needed for confident, on-the-spot decision making for better outcomes.
POC test streamlines workflow
The use of POC tests, however, is not limited to the ED or hospital and there is increasing demand, for example, from clinicians to use POC testing systems for both acute and chronic conditions [6].
- While the areas of medicine covered by near-patient testing are exponentially increasing, in each case the objective is the same:
- Speed up the availability of results allowing for on-the spot clinical decision, so that clinicians can act without delay
- Improve patient satisfaction and reduce waiting time
- Streamline workflow and achieve greater overall efficiency of resources.
Two more extensions to the Minicare family are expected to be available in the second half of 2017:
Minicare H-300* point-of-care thromboelastography system:
to aid in the diagnosis and monitoring of hemostasis abnormalities. In critical care situations, such as a heavy blood loss, trauma or before, during and after surgery, understanding a patient’s hemostatic status is critical. Philips will offer a point-of-care hemostasis system that delivers real-time insights in the whole blood hemostasis status of the patient. This novel, small footprint, portable system delivers full results within 15 minutes, with the first results already visible within five. Unlike current hemostasis analysers which are complex to operate, this device is easy to use with minimal training. It is suitable for both the operating room and the ED.
Minicare C-300 clinical chemistry system with an extensive range of chemistry parameters:
Clinical chemistry testing can now be done near-patient with this small benchtop, point-of-care clinical chemistry system for rapid and efficient near-patient testing and diagnosis. Now there’s no need to send blood samples to the central lab and wait for them to return. Shorter waiting time for blood test results is likely to improve workflow and the overall patient experience. Within 15 minutes, the Minicare C-300 will deliver results for an extensive range of clinical chemistry parameters, with a good correlation to the central laboratory instruments. It is easy to operate with limited sample preparatory work required.
Improving patient care
In-vitro diagnostics tests at the point of care provide clinically significant information faster than is possible from the central laboratory. Near-patient testing offers the potential to improve levels of patient’ satisfaction with their treatment, while making more efficient use of healthcare resources [1]. As a global leader in health technology, Philips is expanding its Minicare family of IVD near-patient testing systems for a range of clinical care settings – from critical care in (pre) hospital acute care to primary care. The Philips message is to develop IVD POC solutions ‘ready where you are’, enabling near-patient testing to play a key part in improving patient’s experience.
References
1. Laurence, Caroline O et al. “Patient Satisfaction with Point-of-Care Testing in General Practice.” The British Journal of General Practice 60.572 (2010): e98–e104. PMC. Web. 17 Aug. 2017.
2. World Health Organisation. The Global Burden of Disease. Updated 2004. Available at: www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf accessed July 2017
3. European Society of Cardiology. ESC Guidelines. Updated 2016. Available at: www.escardio.org/Guidelines/Clinical-Practice-Guidelines accessed July 2017
4. Bingisser R, Cairns C, Christ M, Hausfater P, Lindahl B, Mair J, Panteghini M, Price C, Venge P. Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am J Emerg Med. 2012 Oct;30 1.
5. Cowie M. R., et al. (2014) Improving care for patients with acute heart failure: before, during and after hospitalization, ESC Heart Failure, 1, 110–145, doi: 10.1002/ehf2.12021.
6. Howick J, et al. (2014). Current and future use of point-of-care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA. BMJ Open. 4:8. (8):1639-49. doi: 10.1016/j.ajem.2012.03.004. Epub 2012 May 23.
Philips Medical Systemswww.healthcare.philips.com
*Philips is distributor and Entergrion is legal manufacturer
The frontiers of radiology – connecting patients
/in Featured ArticlesThe march of healthcare technology is not always even. Benefits on one front can often be outweighed by problems on another. Radiology is no exception to this rule.
Like other medical professionals, radiologists have begun using portals and social media to connect to patients and join the move towards personal healthcare.
Websites and radiology
Today, websites staffed by imaging professionals seek to directly address the public about radiology. Such a trend is especially pronounced in the US. Examples include radiology Q&A portals at the University of Texas’ John P. and Kathrine G. McGovern Medical School, Northwest Radiology Consultants in Atlanta, Georgia, and a host of others. One of the best known is the RSNA/ACR public information website, RadiologyInfo.org, which offers a library of resources for patients including information on how various imaging procedures are performed. In Europe, the ESR has a Website page dedicated to ‘Radiation and Patients’ and an ‘Ask EuroSafe Imaging’ Q&A page, split into three sections (CT, interventional radiology and pediatric imaging), with answers provided by radiologists from across the continent.
Radiologists and social media
Radiologists have also sought to use social media to build and continuously strengthen interactive relationships with patients outside a formal hospital or physician office setting. Such approaches have spilt over into tackling concerns after widespread reports in the media about the ‘over-use’ of medical radiation. In the US, for example, the Health Physics Society has a site dedicated largely to addressing such risk perceptions in the general public. The UK too has seen such a step with the British Institute of Radiology and the Institute of Physics and Engineering in Medicine endorsing Ask for Evidence, as part of which a panel of radiologists and medical physicists respond to questions from the public on radiation safety.
Technology versus patient downtime
These are clearly significant and laudable developments. Informed patients are increasingly regarded to be better patients by several physicians. However, other recent developments in technology, above all electronic medical/health records (EMR/EHR), are placing a growing burden on clinicians to update medical documentation, in order to facilitate real-time sharing and reduce errors. This results in less time for patient care. A key driver here, in the US, consists of federal government meaningful use (MU) requirements, which provides physicians with financial incentives to use EHRs.
For radiologists, these incentives are hardly negligible and range from 44,000 to 63,750 dollars (39,000 to 56,735 Euros) over a 5-or 6-year period via Medicare and Medicaid, respectively.
On the other hand, MU also requires 10% of patients viewing, downloading or transmitting their electronic health information, with over 40% of all imaging scans to be made accessible via certified EHR technology.
The above requirements are hardly a testimonial to efficiency. One study on MU published by the Radiological Society of North America (RSNA) in 2012 found that medical residents reported having to spend the bulk of their time updating charts and documentation, and that EHR adoption correlated directly to reduced time for direct patient care.
Radiology strives to remain at technology cutting edge
This is a profound challenge. Radiology has traditionally been the medical speciality at the cutting edge of technical advancement. It was radiology which first moved away from paper to digital technology. As a result, radiologists and industry are currently seeking to fast track solutions for increasing patient downtime and improving workflow.
Data use
In the first stage, the focus was on enhancing use of available data. Ironically, illustrating the unevenness and asynchronicity in the progress of technology, efforts were concentrated on getting more usable data out of electronic records, which did not always trickle down to radiologists. One reason was the lack of skills. Referring physicians often left responsibility to get approval for imaging to office staff, many of of who lacked the clinical knowledge required to seek such approval.
Automation: From CPOE to CDS
Soon after, the effort shifted to automation, especially in the shape of decision support (and so-called assistant clinical reasoning) tools. Such a process continues, with evolution from static to dynamic, patient-centred tools. A good example of this is the computerized order entry (CPOE) system. In 2012, a study in the ‘Journal of the American College of Radiology’ proved the clinical viability of combining radiology CPOE with imaging decision support, including pathways and algorithms, as well as classification for actionable findings.
One of the longest-used clinical decision support systems is ACR Assist from the American College of Radiology, which is designed to blend in seamlessly with radiology workflow. Clinical data is encoded in vendor-neutral ways, in order to quickly build commercial applications. The ACR has since created guidelines for radiologists and referring physicians to proceed after clinical findings. Others are also stepping in with new initiatives to enhance automation and decision support. Massachusetts General Hospital, for example, has developed Procedure Order Entry (PrOE), a surgical appropriateness system to help identify whether a procedure is necessary, and the implications of this for radiology are under active investigation. By utilizing evidence-based guidelines rather than have a less-informed entity authorize diagnostic imaging, CPOE in radiology not only enhances efficiency, but also the quality of care.
IPads and speed
One unexpected finding cited in the 2012 RSNA study on meaningful use was that residents using iPads were able to enter and update data more rapidly. Indeed, a majority of those surveyed found that iPads led to significant increases in work efficiency.
This was an opportune moment, given that a year previously, the US Food and Drug Administration had cleared the first mobile app to allow physicians to make diagnoses using iPads or iPhones.
Currently, radiology imaging applications for mobile platforms allow remote monitoring and control for a PACS administrator. Fuelled by standard tools such as DICOM viewers, these impact directly on quality control, data management and workflow efficiency.
The implications of teleradiology connectivity are especially dramatic in emergency settings. About five years ago, Mayo Clinic physicians deployed smartphones in order to assess their utility in a telemedicine stroke-management network which connected radiologists to neurologists and emergency physicians at a remote facility. The findings were encouraging, with over 90% of agreement on the key radiological findings. In the future, smartphone-based teleradiology systems are likely to become commonplace among first responders.
Image management and automation
Image management is also being used as a means to automate processes. The fast growth of technology has also necessitated unprecedented collaborations between specialists. Oncologists, for example, have been working with radiologists to analyse datasets for tumour detection and monitoring, and some studies report sharp reduction in the time required to study suspicious tissue.
On its part, Massachusetts General has also developed QPID (Queriable Patient Interface Dossier) to integrate electronic records and streamline providers’ abilities to access details in a patient’s medical history.
Other areas for attention include voice-enabled documentation, accompanied by structured reporting and data sets that pre-populate a radiology report. These not only reduce human error when inputting data but also enables radiologists to interpret and diagnose a study when a referring physician is most in need of the information – while meeting a patient.
From automation to deep machine learning
The greatest benefit of automation is to maximize the use of available data. This enhances the ability to provide not just personal but precision medicine, too. When interfaced to an appropriate radiology-focused IT platform, individual radiologists and the broader radiology (as well as clinical) community will be empowered to benefit from feedback loops that reinforce positive lessons, de-emphasize negative ones and continuously build appropriateness and best-practice guidelines. Based on the templated information in a report, colleagues (real and virtual) would be able to rapidly offer second opinions and perspectives on how to best serve a specific patient-case.
Further down the road are deep machine learning tools which will provide sophisticated, structured and in-depth data on a patient, to enable increasingly informed decisions in the context of specific and individual challenges – influenced by factors ranging from pharmacogenomics to disease staging, age and lifestyle. Such knowledge, which would create highly actionable reports, are expected to dramatically impact upon patient outcomes.
Radiology and public perception
It is no secret that professional radiological societies strongly believe there is a need to improve patient (and public) perception of the role played by radiologists in healthcare, and that this necessitates closer contact with patients. Patients after all seldom choose a radiologist. This choice is made by a referring physician or health plan.
Though radiology is essential to patient care, radiological services often seem inconvenient, a threat to privacy, sometimes mysterious and scary. The connect between a radiologist and patient is intermediated by nurses and assistants (e.g. for injecting contrast material or preparing them for the imaging procedure), or by technologists seen as managers of machines. Various studies have shown that radiologists are not always present during performance of a study and seldom introduce themselves to a patient.
As a result, patients increasingly consider radiologists to be supervisors of a technological process. The clinician requesting the examination and receiving the radiology report is considered to be the one interpreting the study and making the decision.
Patient at the core
To sum up, the core value proposition in transforming and keeping radiology up to date involves the patient. Although the growing digitization of healthcare pushes radiologists away from patients, there is a need to make these interactions more prominent. Some radiologists warn that otherwise, there is a risk of their services becoming commoditized. For such a process, there is clearly a need to draw more patient data into decision-making. One of the most ambitious efforts on this count was launched at the turn of the decade by RSNA, with funding from the National Institute of Biomedical Imaging and Bioengineering. The project, which promotes patient access to self-management tools, is known as Image Share, and consists of a secure network based on open-standards architecture. Images are exchanged between servers at radiology departments and imaging centres via the Cloud. A two-year pilot began in 2011 at Mount Sinai Medical Center in New York, followed by university hospitals in several states. In 2016, RSNA introduced a validation programme for the project, to test vendor system compliance with standards for exchange of medical images. To date, results have been satisfying.
Although initiatives like this will continue to grow in importance, they are unlikely to do more than enhance the efficiency of radiologists – and their professional judgement – in improving patient care.









